EGFR and colorectal carcinoma: Indeed, patients with metastatic CRC harboring KRAS or NRAS mutations are excluded from targeted therapies with anti-EGFR drugs, such as Cetuximab®7, and among patients with non-mutated CRC, only half will benefit of this therapy.